9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

Study design incorporates two primary endpoints to evaluate the efficacy of vurolenatide in short bowel syndrome with or without parenteral support dependenceStudy design allows for the assessment of the

Related Keywords

United States ,America ,Al Medwar ,John Temperato ,Patrickh Griffin ,Veronica Eames ,National Institute Of Diabetes ,Linkedin ,Meters Biopharma Inc View ,Drug Administration ,Meters Biopharma Inc ,Nasdaq ,Lifesci Communications ,Facebook ,Investor Relations Corporate Communications ,North America ,Chief Medical Officer ,New Drug Application ,Review Board ,Chief Executive ,National Institute ,Kidney Diseases ,Annual Report ,Quarterly Reports ,Investor Relations ,Corporate Communications ,Sci Communications ,Inc View ,Meters ,Iopharma ,Nnounces ,Hase ,Study ,Urolenatide ,Short ,Towel ,Yndrome ,